Vitamin B12
Vitamin B12 (cobalamin) is a water-soluble B vitamin found almost exclusively in animal foods. The body uses it for red-blood-cell formation, normal nervous-system function, and energy metabolism. UK NHS reference intake is 1.5 µg/day for adults — small amounts, but absorption is intricate. Vegans, older adults with reduced stomach-acid production, and people on long-term metformin or proton-pump inhibitors are the populations most at risk of low levels.
Camden Medicals editorial · Last reviewed 12 July 2026 · Next review July 2027
- Cross-checked against
- NHS
- NICE
- BNF
- EFSA
- FSA
Camden's editorial team independently graded each health claim below on the strength of the published evidence — see the grade beside every condition.
- Class
- Vitamin
- NHS daily RNI
- 1.5 µg
- Typical supplemental
- 1.5-500 µg/day depending on context (food-replacement vs supplement-only diet vs absorption issues)
- Top use evidence
- Strong
On this page
What it is
Vitamin B12 is absorbed through a tightly-regulated pathway: dietary B12 binds intrinsic factor — a glycoprotein made by the parietal cells of the stomach — and is then taken up in the terminal ileum. A small amount (~1% of an oral dose) is also absorbed by passive diffusion across the intestinal wall, which is why high-dose oral B12 (500–1,000 µg/day) can work for diet-related deficiency even when intrinsic factor is partially impaired — but NOT for pernicious anaemia, where NHS practice is intramuscular hydroxocobalamin.
When B12 status sits in a borderline serum range, the functional markers methylmalonic acid (raised) and homocysteine (raised) become elevated and can confirm a true low-B12 picture. High-dose folate (≥1 mg/day) can correct the megaloblastic anaemia caused by B12 deficiency without correcting the underlying B12 problem — potentially allowing neurological damage to progress silently. UK guidance therefore recommends checking B12 status before supplementing high-dose folate.
Vitamin B12 is a family of cobalt-containing molecules called cobalamins. The two active forms in human metabolism are methylcobalamin (used in the cytoplasm to recycle homocysteine to methionine) and adenosylcobalamin (used in mitochondria for amino-acid metabolism). Supplements typically contain cyanocobalamin (cheap, stable, converts efficiently to active forms once absorbed), methylcobalamin (active form, sometimes marketed as "more bioavailable"), or hydroxocobalamin (the form used in NHS injections).
UK food sources are limited to animal products: red meat, fish, eggs, dairy, and fortified foods (some plant-milks, breakfast cereals, nutritional yeast). Plants do not reliably synthesise B12; trace amounts in seaweeds and fermented foods are not considered a reliable dietary source.
Absorption depends on intrinsic factor — a glycoprotein made by the parietal cells of the stomach. Without intrinsic factor (e.g. in pernicious anaemia, after gastric surgery), oral B12 is poorly absorbed and replacement is given by injection.
At a glance
- NHS adult RNI 1.5 µg/day. Routine UK food sources: meat, fish, eggs, dairy.
- Plant foods do not reliably contain bioavailable B12 — vegans should supplement (NHS guidance).
- Long-term low B12 can cause megaloblastic anaemia and neurological problems; symptoms can take years to appear and partially overlap with folate deficiency.
- For supplementation, methylcobalamin and cyanocobalamin both work — the body converts cyanocobalamin to active forms readily; the cost difference often does not buy meaningful clinical benefit.
What people use it for
Vegans and strict vegetarians
NHS guidance recommends supplementation or fortified foods. Plant diets do not reliably supply B12; without intervention, risk of deficiency rises over years. [1]
Some evidenceStrongAdults over 50-60 with reduced stomach-acid production
Atrophic gastritis (more common with age) reduces B12 absorption from food, even when total intake is adequate. Synthetic B12 in fortified foods or supplements is more readily absorbed and can sensibly bridge the gap. [3]
Some evidenceModeratePeople on long-term metformin or proton-pump inhibitors (PPIs)
Both classes of medicine can reduce B12 absorption over years. NICE CKS lists metformin, PPIs, H2-receptor antagonists, colchicine, and nitrous oxide among drug-related causes of B12 deficiency. Periodic monitoring of B12 levels is reasonable; talk to your prescriber. [3]
Some evidenceModeratePregnancy and breastfeeding
NHS adult RNI is unchanged in pregnancy (1.5 µg/day) but rises to 2.0 µg/day during breastfeeding (UK COMA 1991 DRVs, retained by SACN). Adequacy matters for the developing nervous system; vegan and vegetarian women should ensure intake from supplements or fortified foods. [1,6]
Some evidenceStrongPeople with diagnosed B12 deficiency or pernicious anaemia
NHS pathway: hydroxocobalamin injections, not OTC supplements. Suspected deficiency should be investigated by a GP — symptoms overlap with other conditions and OTC self-treatment can mask the diagnosis. [2]
Some evidenceStrong
How it works
B12 is a co-factor for methionine synthase (homocysteine to methionine) and methylmalonyl-CoA mutase. Through methionine, B12 underpins one-carbon metabolism — DNA synthesis, methylation reactions across the body. Functional deficiency disrupts red-blood-cell maturation (megaloblastic anaemia) and myelin maintenance (subacute combined degeneration of the spinal cord). Both processes take time to develop after intake drops, which is why deficiency can be silent for years.
Common myths
Myth"Methylcobalamin is dramatically better than cyanocobalamin"
RealityThe body converts cyanocobalamin to active forms (methylcobalamin and adenosylcobalamin) readily; the cyanide moiety is excreted in trivial amounts. Pharmacokinetic differences between the two oral forms exist but are modest (Paul & Brady 2017). NHS B12 injections in the UK use hydroxocobalamin specifically because of its longer plasma half-life — a different consideration from oral routine supplementation. The "methyl is better" framing is largely marketing. [7]
Myth"High-dose oral B12 is enough for pernicious anaemia"
RealityIn pernicious anaemia, intrinsic factor production is the bottleneck; some passive absorption of high-dose oral B12 occurs, but UK NHS practice for pernicious anaemia is hydroxocobalamin intramuscular injection. Self-treatment with oral high-dose B12 risks under-treatment. See your GP for a confirmed diagnosis and the right pathway. [2]
Myth"Energy drinks with B12 give you more energy"
RealityB12 is needed for normal energy-yielding metabolism — that means it is required for the system to work, not that supplementing above adequacy produces an above-normal effect. The boost from an energy drink, if any, is from caffeine and sugar, not from the B12 added. [5]
Myth"Plant foods like seaweed or fermented soy provide reliable B12 for vegans"
RealityTrace cobalamin-like compounds appear in some seaweeds and fermented foods, but bioavailability is unreliable and many are inactive cobalamin analogues that compete with active B12 for binding (Watanabe 2014). NHS guidance for vegans is to use fortified foods or supplements as the dependable source. [8]
Common online questions
Synthesised from the questions UK shoppers most often ask online about Vitamin B12. Each answer is editorial and links to its evidence in the Sources list below.
Do I need to take B12 if I'm vegan?
Yes — and this is one of the few unambiguous "yes" answers in supplement nutrition. Vitamin B12 is produced by bacteria; it does not occur reliably in plant foods. NHS guidance for vegans is to use fortified foods (some plant milks, nutritional yeast, breakfast cereals) or a supplement as the dependable source. The same applies to long-term strict vegetarians who avoid eggs and dairy. [1]
Will B12 supplements give me more energy?
Only if you are deficient. The GB-authorised claim is that B12 contributes to "the reduction of tiredness and fatigue" — a claim about adequacy supporting normal function, NOT a claim that supplementation in non-deficient adults boosts energy beyond replacement. If you feel tired, the most useful first question is whether you have a B12 deficiency (a GP blood test can tell you), iron-deficiency anaemia, thyroid issues, sleep problems, or another underlying cause — supplementing without a reason rarely changes how you feel. [5]
Methylcobalamin vs cyanocobalamin — does it matter?
For routine repletion in healthy adults, the practical difference is small. The body converts cyanocobalamin to the active forms (methylcobalamin and adenosylcobalamin) readily; the cyanide moiety is excreted in trivial amounts. NHS B12 injections in the UK use hydroxocobalamin specifically because of its longer plasma half-life — a different consideration from oral routine supplementation. The "methyl is dramatically better" framing is largely marketing. [7]
Are sublingual or spray B12 supplements more effective?
The evidence is limited. Some pharmacokinetic studies show comparable absorption between sublingual and standard oral tablets — both rely partly on the ~1% passive-diffusion absorption that does not require intrinsic factor. There is no robust head-to-head clinical-outcome data showing one format is meaningfully more effective than the other for the same daily dose. For people with proven absorption problems (e.g. pernicious anaemia), NHS practice is intramuscular injection regardless of the oral format.
I take metformin for diabetes — should I supplement B12?
Long-term metformin reduces B12 absorption (NICE Clinical Knowledge Summaries lists metformin among drug-related causes of B12 deficiency). Periodic B12 monitoring is reasonable; ask your GP or pharmacist whether your local pathway recommends a check. Whether to start a supplement before a check is a clinical decision — talk to your prescriber. [3]
Can I get all my B12 from algae or seaweed?
Mostly no. Trace cobalamin-like compounds appear in some seaweeds and fermented foods, but bioavailability is unreliable and many of these are inactive cobalamin analogues that compete with active B12 for binding (Watanabe 2014). NHS guidance for vegans is to use fortified foods or supplements as the dependable source — algae is not. [8]
Hydroxocobalamin vs methylcobalamin — which is better?
For everyday oral supplementation, the published evidence does not establish one form as clinically superior to another. A 2017 review of B12 forms (Paul and Brady) describes how methylcobalamin, hydroxocobalamin, adenosylcobalamin and cyanocobalamin are all reduced inside the body to a common cobalamin core and then converted to the two active coenzyme forms in a ratio that does not depend on which form was taken. Hydroxocobalamin is the form the NHS uses for B12 injections, chosen for its longer plasma half-life once given by injection — a consideration specific to injections, not a sign that hydroxocobalamin works better as an oral tablet. How well any form is absorbed can also vary between people for reasons such as gut conditions, age and genetics. The "one form is dramatically better" message common in marketing is not supported by robust head-to-head clinical-outcome data for routine oral use. [7,9]
How many types of B12 are there?
The B12 (cobalamin) family is usually described in terms of four forms. Two of them — methylcobalamin and adenosylcobalamin — are the active coenzyme forms the body uses directly (methylcobalamin in the cytoplasm, adenosylcobalamin in the mitochondria). The other two are cyanocobalamin, the inexpensive and very stable form most common in supplements and fortified foods, which the body converts to the active forms once absorbed; and hydroxocobalamin, the form used in NHS B12 injections. All four are made by bacterial fermentation, so all are suitable for vegans. This entry's "forms" section sets out each one.
⚖️ The official position
What may lawfully be claimed about Vitamin B12 in Great Britain. This is a regulatory position, not an evidence grade.
A health claim is authorised in Great Britain.
“Vitamin B12 contributes to the reduction of tiredness and fatigue”
“Vitamin B12 contributes to normal psychological function”
“Vitamin B12 contributes to normal functioning of the nervous system”
“Vitamin B12 contributes to normal energy-yielding metabolism”
“Vitamin B12 contributes to normal homocysteine metabolism”
“Vitamin B12 contributes to the normal function of the immune system”
“Vitamin B12 contributes to normal red blood cell formation”
“Vitamin B12 has a role in the process of cell division”
This claim is authorised for use in Great Britain under the GB Nutrition and Health Claims regulation. A product may carry it when it provides at least 15% of the UK NRV per recommended daily portion.
Authorised UK health claims
Verbatim from the GB Nutrition and Health Claims Register (Reg 432/2012 as assimilated in GB). A product can carry these claims when it provides at least 15% of the UK NRV per recommended daily portion.
8 authorised claims — show / hide
- "Vitamin B12 contributes to the reduction of tiredness and fatigue"
- "Vitamin B12 contributes to normal psychological function"
- "Vitamin B12 contributes to normal functioning of the nervous system"
- "Vitamin B12 contributes to normal energy-yielding metabolism"
- "Vitamin B12 contributes to normal homocysteine metabolism"
- "Vitamin B12 contributes to the normal function of the immune system"
- "Vitamin B12 contributes to normal red blood cell formation"
- "Vitamin B12 has a role in the process of cell division"
Camden guides citing Vitamin B12
Editorial pieces from the Camden blog that reference Vitamin B12. Each guide cites the evidence it draws on.
Vitamin B12 Forms: Methylcobalamin vs Cyanocobalamin vs Hydroxocobalamin
April 2026
Read the guide →High-Dose Biotin and Your Blood Tests: Why Your Supplement Might Skew a Heart-Attack Diagnosis
April 2026
Read the guide →Magnesium Glycinate vs Citrate vs Oxide: Which Form Actually Does What
April 2026
Read the guide →The Gut Microbiome: What It Is, Probiotics That Actually Work, and the Boring Answer That Helps Most
April 2026
Read the guide →Gluten Explained: Coeliac Disease, Wheat Allergy and Non-Coeliac Sensitivity
April 2026
Read the guide →Paracetamol vs Panadol: Why Generic Medicines Work Just as Well
April 2026
Read the guide →
🔬 Camden’s evidence review
The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.
Cognitive function in adults with low or borderline-low B12
LimitedEvidencelimitedCorrection of clinical B12 deficiency improves the haematological and neurological problems caused by deficiency. The Cochrane review (Malouf & Areosa Sastre, CD004326) found insufficient evidence that B12 supplementation improves cognitive function in people without B12 deficiency. [10]
Energy / fatigue in adults with normal B12 levels
InsufficientEvidenceinsufficientThe authorised UK claim is that B12 contributes to "the reduction of tiredness and fatigue". This is a function-of-adequacy claim (EFSA NDA Panel 2010 opinion underlying GB NHC), not a claim that supplementation in non-deficient adults reduces fatigue beyond replacement. [5]
Cardiovascular outcomes via homocysteine lowering
InsufficientEvidenceinsufficientB12 with B6 and folate lowers homocysteine, but Cochrane (Marti- Carvajal CD006612) and other large randomised trials have not shown reductions in major cardiovascular events from this lowering in non-deficient adults. [11]
Diabetic peripheral neuropathy
LimitedEvidencelimitedTrials in diabetic neuropathy with methylcobalamin (sometimes combined with L-methylfolate and vitamin B6) have shown modest symptomatic improvement in some studies; effect size is small and clinical practice is not standardised. Investigate B12 levels in this group (PPIs and metformin are common co-prescriptions). [12]
Effect matrix — per-condition evidence
Per-outcome summary of the published trial corpus: dose ranges studied, duration, evidence grade, and direction of effect. Each row is a citable claim.
| Outcome | Population | Dose | Duration | Evidence | Direction | Sources |
|---|---|---|---|---|---|---|
| Vitamin B12 deficiency correction (haematological and neurological features) | deficient only | 500–1000 mcg | — | LimitedEvidencelimited | improvement | — |
| Guideline-grounded, not trial-pooled. NICE CKS (anaemia-b12-folate-deficiency) and NHS deficiency-anaemia guidance describe correction of a confirmed B12 deficiency improving its haematological (megaloblastic anaemia) and neurological features. High-dose oral B12 (500–1,000 µg/day) is described for diet-related deficiency; where absorption fails (pernicious anaemia), NHS practice is intramuscular hydroxocobalamin, not oral tablets. citations[] is empty because the grounding is UK guideline authority (NICE CKS / NHS), not body-text trial PMIDs — those sources sit in this entry's guidance[] and evidence[] blocks. Grade held at limited: this entry does not appraise the primary deficiency-correction trial corpus. | ||||||
| Cognitive function in adults without B12 deficiency | adults | — | — | InsufficientEvidenceinsufficient | no change | — |
| Cochrane review (Malouf and Areosa Sastre, CD004326) found insufficient evidence that B12 supplementation improves cognitive function in people who are not B12 deficient. Cited as a Cochrane ID rather than a PMID, so citations[] is empty and the grounding sits in the body evidence[] row and clinical_literature. magnitude=no_change reflects the null finding in non-deficient adults. | ||||||
| Cardiovascular events via homocysteine lowering (adults without deficiency) | adults | 400–1000 mcg | 104–260 wk | InsufficientEvidenceinsufficient | no change | PMID 16531613 PMID 16531614 PMID 14762035 |
| Three large secondary-prevention RCTs — HOPE-2 (Lonn 2006, n=5,522), NORVIT (Bønaa 2006, n=3,749) and VISP (Toole 2004, n=3,680) — lowered plasma homocysteine with folic acid plus B6 and B12 (0.4–1 mg B12/day) but showed no reduction in major cardiovascular events over 2–5 years; NORVIT signalled a possible increased-risk trend. Cochrane CD006612 is concordant. B12's authorised GB-NHC claim covers "normal homocysteine metabolism" (a metabolic-adequacy claim), not cardiovascular-event reduction. | ||||||
| Diabetic peripheral neuropathy | adults | 2000 mcg | 24 wk | LimitedEvidencelimited | mixed | PMID 23218892 |
| One multicentre RCT (Fonseca 2012, n=214, 24 weeks) tested a B-vitamin combination — methylcobalamin 2 mg (2,000 µg) plus L-methylfolate and pyridoxal-5'-phosphate — in type-2-diabetic neuropathy. The primary objective measure (vibration perception threshold) did not change significantly, while the patient-reported symptom score (NTSS-6) improved at weeks 16 and 24 — hence magnitude=mixed. The B12 is one component of a combination product, not monotherapy; effect size is small and practice is not standardised. | ||||||
Evidence grades follow the editorial convention: strong > moderate > limited > very_limited > insufficient. Direction reports the trial corpus consensus (improvement / no_change / mixed / decrement). Schema cross-emitted at MedicalSubstance.relevantClinicalCondition[].
Clinical literature review
The vitamin B12 evidence base splits cleanly by population. In people with a confirmed deficiency, UK guidance (NHS, NICE CKS) describes correction improving the haematological and neurological features of the deficiency, with intramuscular hydroxocobalamin the NHS route where absorption has failed (for example pernicious anaemia). In people who are not deficient, the interventional trial evidence is weak: three large secondary-prevention randomised trials — HOPE-2, NORVIT and VISP — lowered plasma homocysteine with folic acid plus B6 and B12 but found no reduction in cardiovascular events, and the Cochrane review of B12 for cognition found insufficient evidence of benefit in non-deficient adults. In type-2-diabetic neuropathy, a single multicentre trial of a B-vitamin combination improved patient-reported symptoms without moving the objective nerve measure. On forms, a 2017 review (Paul and Brady) describes all supplemental cobalamins converging on the same intracellular active forms, consistent with this entry's position that no single oral form is established as superior.
Key trials
Lonn E, Yusuf S, Arnold MJ, et al. · 2006 · N Engl J Med · PMID 16531613
Finding: 5,522 adults with vascular disease or diabetes randomised to folic acid 2.5 mg + vitamin B6 50 mg + vitamin B12 1 mg daily versus placebo. Plasma homocysteine fell 2.4 µmol/L on treatment, but the primary composite of cardiovascular death, myocardial infarction and stroke was unchanged (RR 0.95, 95% CI 0.84–1.07, P=0.41). Stroke was lower (RR 0.75) while hospitalisation for unstable angina was higher (RR 1.24).
Relevance: The largest of the homocysteine-lowering cardiovascular trials; anchors the null cardiovascular-event finding despite reliable homocysteine reduction in non-deficient adults.
Bønaa KH, Njølstad I, Ueland PM, et al. · 2006 · N Engl J Med · PMID 16531614
Finding: 3,749 adults randomised within 7 days of an acute myocardial infarction. Folic acid + B12 lowered homocysteine by 27% but did not change the composite of recurrent myocardial infarction, stroke and sudden coronary death (RR 1.08, 95% CI 0.93–1.25, P=0.31); the folate + B12 + B6 arm showed a trend toward increased risk (RR 1.22, P=0.05).
Relevance: Secondary-prevention post-infarction trial; reinforces the absence of cardiovascular benefit and flags a possible harm signal from combined B-vitamin dosing.
Toole JF, Malinow MR, Chambless LE, et al. · 2004 · JAMA · PMID 14762035
Finding: 3,680 adults with recent non-disabling stroke randomised to a high-dose versus low-dose folate/B6/B12 formulation. Homocysteine was about 2 µmol/L lower on the high dose, but there was no effect on recurrent stroke, coronary events or death (RR 1.0) over 2 years.
Relevance: Stroke-population homocysteine trial; a consistent null cardiovascular result across a third large cohort.
Fonseca VA, Lavery LA, Thethi TK, et al. · 2012 · Am J Med · PMID 23218892
Finding: 214 adults with type-2-diabetic peripheral neuropathy randomised to L-methylfolate 3 mg + methylcobalamin 2 mg + pyridoxal-5'-phosphate 35 mg versus placebo. There was no significant change in the primary objective measure (vibration perception threshold); patient-reported neuropathy symptom scores (NTSS-6) improved significantly at weeks 16 and 24.
Relevance: The B12 here is one component of a combination product, not monotherapy. A mixed result — objective measure null, symptom score improved — that keeps the diabetic-neuropathy grade at limited.
Systematic reviews
- cochrane:CD004326
Cochrane review (Malouf and Areosa Sastre) of vitamin B12 for cognition found insufficient evidence that supplementation improves cognitive function in people who are not B12 deficient.
- cochrane:CD006612
Cochrane review (Martí-Carvajal and colleagues) of homocysteine-lowering interventions found no reduction in cardiovascular events despite lowered homocysteine in non-deficient adults.
- pmid:24667752 · 40 included trials
Pawlak 2014 review of 40 studies reported B12 deficiency prevalence of 0–86.5% in adults across vegetarian and vegan populations, highest among vegans not taking a supplement.
Evidence quality summary
Deficiency correction — guideline-established (NHS / NICE CKS); grade held at LIMITED here because this entry does not appraise the primary correction-trial corpus. Cognitive function in non-deficient adults — INSUFFICIENT (Cochrane CD004326 null). Cardiovascular events via homocysteine lowering — INSUFFICIENT / no change (HOPE-2, NORVIT and VISP null despite homocysteine reduction; Cochrane CD006612 concordant). Diabetic peripheral neuropathy — LIMITED and mixed (single combination-product trial: symptom score improved, objective nerve measure unchanged). Tiredness and fatigue is handled separately as an authorised GB-NHC adequacy claim, not an efficacy grade.
Known gaps
- No head-to-head oral clinical-outcome trials establish any single cobalamin form (methyl-, cyano-, hydroxo- or adenosyl-) as superior for routine repletion.
- Deficiency-correction efficacy rests on UK guidance and established haematology practice rather than a Camden-appraised modern trial corpus.
- The cardiovascular and cognitive trials are in non-deficient populations; they do not speak to outcomes in people who are genuinely B12 deficient.
- The diabetic-neuropathy signal comes from a B-vitamin combination product, so the independent contribution of B12 cannot be isolated.
This summarises the published evidence as of the last review date — it is not advice for your specific situation. Talk to your pharmacist or GP.
Safety
Vitamin B12 has a very high safety margin — the NHS notes that supplemental intakes up to 2 mg/day are unlikely to cause any harm. Suspected B12 deficiency or pernicious anaemia should be investigated by a GP and treated by injection — not self-treated with OTC supplements.
Talk to your pharmacist or GP first if you:
- You have a known cobalt allergy (1–3% of the population is sensitive to cobalt, per the BNF).
- You take long-term metformin or a proton-pump inhibitor (PPI) — both can lower B12 absorption from food over years.
- You take chloramphenicol (may reduce response to B12).
- You take high-dose folic acid (≥1 mg/day) — folate can mask the haematological signal of B12 deficiency. Get B12 status checked first.
- You think you might have B12 deficiency or pernicious anaemia — see your GP. Self-treating with high-dose oral B12 risks under-treating pernicious anaemia and allowing neurological damage to progress silently.
- You are vegan, breastfeeding, or pregnant — adequacy matters for the developing nervous system.
Common side effects: Generally very well tolerated at typical supplemental doses. Rare hypersensitivity reactions to cobalamin formulations.
Pregnancy and breastfeeding
The NHS adult B12 RNI is unchanged in pregnancy (1.5 µg/day) but rises during breastfeeding (2.0 µg/day). Vegan and strict vegetarian women should ensure adequate B12 intake from fortified foods or supplements during pregnancy and breastfeeding for the developing infant's nervous system. As with any supplement, talk to your pharmacist, GP, or midwife before starting.
NHS RNI rises to 2.0 µg/day during breastfeeding.
Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.
More clinical detail (for clinicians and informed readers)
Contraindications
- Known hypersensitivity to cobalamins (cobalt allergy affects 1-3% of the general population per BNF) or any product excipients.
Drug interactions
- Long-term metformin — reduces B12 absorption; monitoring recommended (NICE CKS).
- Long-term PPIs / H2 blockers — reduce B12 absorption from food (less effect on free supplemental B12).
- Chloramphenicol — may reduce haematological response to B12 (BNF caution).
- Colchicine and nitrous oxide (chronic use / repeated exposure) — may reduce B12 absorption or function (NICE CKS).
This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.
Common side effects
- Generally well tolerated at typical supplemental doses.
Rare side effects
- Rare hypersensitivity reactions to cobalamin formulations.
How to take it
- UK Reference Nutrient Intake
- 1.5 µg/day
- Typical supplemental range
- 1.5-500 µg/day depending on context (food-replacement vs supplement-only diet vs absorption issues)
- Timing
- Anytime — water-soluble.
How to spot quality
Look for
- Form named explicitly: cyanocobalamin, methylcobalamin, hydroxocobalamin, or adenosylcobalamin.
- Dose stated in µg with % NRV (UK NRV = 2.5 µg).
- GMP-certified manufacture; ideally third-party potency testing.
- For vegan formulations: clear vegan-source declaration (B12 fermentation feedstocks vary).
Red flags
- Form simply listed as "vitamin B12" with no compound named.
- Marketing that frames methylcobalamin as fundamentally superior without quoting the modest pharmacokinetic differences.
- Energy-drink products marketed as B12 "boosters" — adequacy supports normal energy metabolism, it does not produce supra-normal energy.
- Seaweed-based "vegan B12" without independent assay data — the cobalamin in many seaweeds is unreliable for humans.
Where Camden lands · meets the bar
Camden's NB-1284 (Hair, Skin and Nails) carries 2.5 µg vitamin B12 per serving — that is 100% UK NRV, but at the bottom of the supplemental-dose range. NB-1284 is a beauty-positioned formulation, not a B12-specialist product. Camden does not currently stock a standalone vitamin B12 SKU. Vegans, adults over 50 with absorption concerns, and people on long-term metformin or PPIs would typically want a higher dedicated B12 supplement (10-500 µg/day) — talk to your pharmacist or GP. We are evaluating a standalone NB- vitamin B12 product.
Commonly combined with
Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.
Vitamin B6
Moderate evidenceB12 and B6 share the methionine cycle with folate; deficiency in one tends to mask deficiency in the others.
Vitamin B12 (methylcobalamin) is the cofactor for methionine synthase, which converts homocysteine back to methionine using a methyl group donated by 5-methyltetrahydrofolate. Vitamin B6 (pyridoxal-5-phosphate) is the cofactor for the parallel transsulfuration pathway, where cystathionine beta-synthase converts homocysteine to cystathionine, the precursor of cysteine and glutathione. Adequate status in both vitamins keeps plasma homocysteine within reference range; deficiency in either raises it. The HOPE-2, NORVIT and VISP trials confirmed that combined supplementation lowers measured homocysteine by 2-3 micromol/L on average, but did not reduce major cardiovascular event rates over 2-5 years follow-up.
Evidence: Lonn 2006 (HOPE-2, NEJM 354:1567) randomised 5,522 adults with vascular disease to 2.5 mg folic acid + 50 mg B6 + 1 mg B12 vs placebo for 5 years; homocysteine fell 2.4 micromol/L on treatment but the composite cardiovascular endpoint was unchanged (RR 0.95, p=0.41), with a 25% reduction in stroke offset by a 24% increase in unstable-angina hospitalisation. Bonaa 2006 (NORVIT, NEJM 354:1578) and Toole 2004 (VISP, JAMA 291:565) found similar null cardiovascular results despite confirmed homocysteine reduction. The combined-vitamin effect on homocysteine itself is well-established; the clinical-outcome benefit is not. [13,14,15]
Doses studied: 1.4 mg B6 + 2.5 ug B12 covers UK adult RNI; the homocysteine trials used 25-50 mg B6 + 0.4-1 mg B12 alongside folate.
Methyl Folate (5-Methyltetrahydrofolate)
Strong evidenceB12 and folate are inseparable in the methionine cycle; folate without B12 can mask B12-deficiency anaemia while neurological damage progresses.
Methionine synthase requires methylcobalamin (B12) to transfer the methyl group from 5-methyltetrahydrofolate (the active folate) onto homocysteine, regenerating methionine and releasing tetrahydrofolate for further one-carbon transfers. Without adequate B12, folate becomes trapped as 5-methylTHF (the 'folate trap'), unable to participate in DNA synthesis. Clinically, folate supplementation can correct the macrocytic anaemia of B12 deficiency by bypassing the folate-trap red-cell effect, while leaving the underlying B12 deficiency to progress to subacute combined degeneration of the spinal cord. UK guidance is to confirm adequate B12 status before high-dose folate supplementation in adults.
Evidence: The biochemistry of the folate-B12 interaction is textbook (the 'methyl-folate trap'). The clinical phenomenon of folate-masking-B12 was the basis for fortification debates in the US/UK in the 1990s-2000s and remains the rationale for B12 status checks before initiating high-dose folate, particularly in older adults and in vegans/vegetarians (Pawlak 2014). [16,13]
Doses studied: 200-400 ug methyl-folate + 2.5 ug B12 (UK adult RNI). High-dose folate (>1 mg) should follow B12 status check.
Iron
Moderate evidenceB12 deficiency masks itself as macrocytic anaemia; iron deficiency is microcytic. Co-deficiency can produce a 'normal' MCV that hides both.
Iron is incorporated into haemoglobin and is rate-limiting for erythropoiesis when intake is low. Vitamin B12 is required for DNA synthesis in red cell precursors; deficiency produces megaloblastic (macrocytic) anaemia. When iron deficiency (microcytic, low MCV) and B12 deficiency (macrocytic, high MCV) coexist, the mean cell volume can normalise, hiding the dual deficiency on routine FBC. This is most relevant in vegans and long-term vegetarians, where B12 intake is low (animal-source-only at clinically meaningful doses) and non-heme iron is less bioavailable. Co-supplementation is appropriate where both deficits are confirmed.
Evidence: Pawlak 2014 (Eur J Clin Nutr 68:541) systematic review found B12 deficiency prevalence of 0-86.5% across vegan and vegetarian populations, with vegans at highest risk. Iron deficiency prevalence in vegans/vegetarians is similarly elevated in surveys despite total iron intake often being adequate, due to lower non-heme bioavailability. Combined screening is supported by multiple national dietetic society guidelines. [16,17]
Doses studied: Routine RNI: 8.7 mg iron (men/post-menopausal women) or 14.8 mg (premenopausal women) + 2.5 ug B12. Confirmed deficiency requires individualised dosing under healthcare-professional supervision.
Chlorella (Chlorella vulgaris, Chlorella pyrenoidosa)
Strong evidenceCritical disclosure pairing — chlorella supplementation should be combined with active vitamin B12 (methylcobalamin or cyanocobalamin) in any vegan / plant-based regimen. Same defensive logic as spirulina.
Chlorella corrinoid content is principally pseudo-B12 with some strain-variable methylcobalamin (Watanabe 2014). Reliability is too low for routine vegan B12 status.
A vegan / plant-based regimen including chlorella must include a separate active B12 source. UK BDA and Vegan Society guidance is unambiguous on this point.
The combination is defensive not synergistic. Camden surfaces this combination here so that a consumer reading the chlorella entry has the canonical pairing available immediately.
Evidence: UK BDA, Vegan Society, NHS guidance all support the position that chlorella is NOT a reliable B12 source and active B12 supplementation is required in vegan / plant-based regimens. [2]
Doses studied: Chlorella at user-chosen dose (3-6 g/day cell-wall-cracked) PLUS active vitamin B12 (methylcobalamin or cyanocobalamin) 25 µg/day, or 1000 µg twice weekly, or 2000 µg weekly.
Choline
Moderate evidenceOne-carbon methylation cluster — folate, B12, B6, and choline form the core homocysteine-regulation set.
Methionine synthase (the principal homocysteine-remethylation enzyme) requires vitamin B12 as a cofactor. Choline via betaine provides an alternative methyl-donor route via BHMT. The two routes are biochemically parallel and clinically complementary — sustained low B12 reduces flux through methionine synthase and increases reliance on the BHMT pathway, requiring adequate choline.
Both have UK Article 13.1 authorised claims for homocysteine metabolism. The combination appears in many UK general multivitamins and in pregnancy / preconception bundles.
Evidence: Mechanism well-established. UK Article 13.1 authorised homocysteine claim for B12 (gb-nhc:vitamin_b12). [5]
Doses studied: 2.5-1000 µg/day vitamin B12 (methylcobalamin or cyanocobalamin) + 100-450 mg/day choline.
NMN (β-Nicotinamide Mononucleotide)
Insufficient evidenceB12 is the regulatory anchor for any fatigue / energy framing on a multi-active NMN SKU — the EFSA-permitted claim attaches to B12, not to NMN.
Vitamin B12 (cobalamin) carries authorised EFSA health claims including reduction of tiredness and fatigue, normal energy- yielding metabolism, and normal psychological function. In a multi-active SKU containing NMN and B12, regulatory framing for energy / fatigue / cognition attaches to the B12, not to the NMN. This is a regulatory pairing, not a synergy claim.
Evidence: EFSA-authorised claims for B12 are settled regulatory positions. NMN itself has no authorised UK food-supplement health claims.
Doses studied: B12 100% NRV minimum to anchor a permitted claim; Camden NB-161 supplies 6,000% NRV at 150 µg methylcobalamin per capsule. NMN itself is a novel food under assessment and not authorised for GB sale — see the novel-food note on the NB-161 listing.
Spirulina (Arthrospira platensis, Arthrospira maxima)
Strong evidenceCritical disclosure pairing — spirulina supplementation should be combined with active vitamin B12 (methylcobalamin or cyanocobalamin) in any vegan / plant-based regimen. The combination corrects the pseudo-B12 misperception.
Spirulina contains pseudo-B12 corrinoid analogues that are NOT human-bioavailable as active vitamin B12. Active vitamin B12 (methylcobalamin or cyanocobalamin) is required for normal methionine synthase and methylmalonyl-CoA mutase function — the substrates of the B12-deficiency clinical syndrome (megaloblastic anaemia, peripheral neuropathy, subacute combined degeneration of the cord, depressive symptoms).
A vegan or plant-based regimen including spirulina must include a separate active B12 source — methylcobalamin or cyanocobalamin supplements (typically 25 µg/day daily, or 1000 µg/week intermittent), or B12-fortified foods. UK BDA and Vegan Society guidance is unambiguous on this point.
The combination is therefore not synergistic — it is defensive. Camden surfaces this combination here so that a consumer reading the spirulina entry has the canonical pairing available immediately.
Evidence: UK BDA, Vegan Society, NHS guidance all support the position that spirulina is NOT a B12 source and active B12 supplementation is required in vegan / plant-based regimens. [2]
Doses studied: Spirulina at user-chosen dose (1-6 g/day) PLUS active vitamin B12 (methylcobalamin or cyanocobalamin) 25 µg/day, or 1000 µg twice weekly, or 2000 µg weekly. Camden's vitamin-b12 entry covers the dosing rationale.
St John's Wort (Hypericum perforatum)
Limited evidenceB12 deficiency mimics depression — a screen-and-treat-deficiency-first principle. B12 is included in mood supplements alongside St John's Wort to cover the deficiency overlap.
Vitamin B12 deficiency (and folate deficiency, with which it shares the methylation pathway) can produce depressive symptoms, fatigue, and cognitive dulling indistinguishable from primary depression. UK GP practice on suspected depression includes a B12 / folate / ferritin screen specifically because deficiency is a treatable mimic.
B12 in a mood formulation is not synergistic with St John's Wort; it is a deficiency-cover mechanism — making sure that an underlying B12 deficiency is not the cause of the low mood the user is hoping the formulation will address. The two do not interact pharmacokinetically. UK Article 13 authorised claim: "Vitamin B12 contributes to normal psychological function".
Evidence: The B12-deficiency-mimics-depression literature is well-established (NHS GP guidance includes B12 in depression workup). Direct B12 + St John's Wort combination trials on mood are not published. [5]
Doses studied: 2.5-1000 µg/day vitamin B12 (UK NRV 2.5 µg; methylcobalamin or cyanocobalamin) alongside standardised St John's Wort. The B12 dose is for nutritional sufficiency, not pharmacological mood effect.
Trimethylglycine (TMG / Betaine anhydrous)
Strong evidenceB12 + TMG together complete the homocysteine-remethylation picture (folate/B12 pathway via methionine synthase + TMG/BHMT pathway).
Homocysteine remethylation has two parallel pathways: (1) methionine synthase (B12-dependent), and (2) BHMT (TMG- dependent). Both regenerate methionine from homocysteine. Camden NB-161 supplies both — 150 µg B12 (6,000% NRV) and 600 mg TMG — covering both pathways for users who may have either pathway limitation.
Evidence: Both pathways are settled biochemistry. EFSA-authorised B12 claims include normal homocysteine metabolism. The TMG Article 13.5 claim has the same theme but is conditional on the 1.5 g threshold. [18,19,20]
Doses studied: B12 100% NRV + TMG 500–2000 mg daily.
Vitamin B1 (Thiamine)
Moderate evidenceB-complex cluster — B1 + B12 nervous-system function.
Both UK Article 13.1 nervous-system function authorised. Mechanism complementary.
Evidence: UK Article 13.1 claims both. [5]
Doses studied: 1.4 mg B1 + 2.5 µg B12 daily (UK NRV).